Library · Metabolic & weight · Treatment of obesity and type 2 diabetes
Survodutide (BI 456906)
BI 456906, BI456906, Survodutide
A dual glucagon/GLP-1 receptor agonist (BI 456906) from Boehringer Ingelheim and Zealand Pharma. It combines glucagon-driven energy expenditure with GLP-1-driven appetite suppression for weight management and metabolic dysfunction–associated steatohepatitis.
Research score 85/100. Reference only, not a dose.
- Appetite Suppression
- Blood Sugar Control
- Metabolic Enhancement
- GLP-1 Agonist
- Weight Loss
- US status
- Investigational
- Approval
- Phase 2 Clinical Trial
- Evidence
- Phase 3 trials ongoing (SYNCHRONIZE). Strong weight loss and liver fat reduction data.
- Research score
- 85 / 100
- Indication
- Investigational - Type 2 Diabetes Mellitus
- Origin
- Germany
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
GLP-1 receptor activation raises glucose-dependent insulin release, cuts glucagon, slows gastric emptying, and promotes satiety via the hypothalamus; glucagon receptor activation adds energy expenditure and fat oxidation through liver glucose production and thermogenesis; structural modifications extend its half-life.
Safety file
GI effects such as nausea, diarrhea, and vomiting are common and dose-related; some trials saw higher discontinuation due to GI issues.
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions